Cell and Gene Outsourcing

  1. Linking Clinical Correlates To Cell Therapy Outcomes 6/9/2025

    Streamline cell therapy development by transforming complex cellular characteristics into a predictive, multiparametric metric that guides the selection of high-potential starting material.

  2. 5 Key Considerations For Companies Outsourcing Process Development 6/9/2025

    Venture capital in biotech remains strong post-pandemic, especially in cell and gene therapies. Discover five key factors to help companies choose between in-house and outsourced process development strategies.

  3. Lyophilization To Enable Drug Products Containing Labile Molecules 6/6/2025

    Develop lyophilized formulations to overcome stability challenges and significantly extend the shelf life of sensitive therapeutic products.

  4. Injection Site Reaction Screening Methodology 6/6/2025

    Optimize drug formulations for solubility at physiological pH to reduce injection site reactions, enable high-concentration dosing, and enhance patient comfort and compliance.

  5. Extractables And Leachables 6/6/2025

    Ensure the safety, quality, and regulatory compliance of your pharmaceutical or medical products with robust extractables and leachables testing tailored to identify potential risks under both exaggerated and real-use conditions.

  6. Aseptic Fill-Finish 6/6/2025

    Whether you are navigating technical hurdles, scaling production, or preparing for market launch, our integrated approach ensures a seamless path from bench to bedside.

  7. Bioanalytical Development And Testing For LNPs 6/6/2025

    Streamline gene therapy development by partnering with a centralized, GLP-compliant bioanalytical lab for comprehensive biodistribution studies using techniques like LC-MS/MS, RT-qPCR, and ELISA.

  8. Fill-Finish Contract Manufacturing: Trends, Challenges, And The Future 6/6/2025

    See why it's important to partner with a CDMO that’s investing in advanced sterile fill-finish capabilities to meet the demands of complex biologics, gene therapies, and mRNA-based products.

  9. DOE Methodology Reduces Cost, Time For Analytical Method Development 6/5/2025

    Here, we illustrate how our Design of Experiment (DoE) can accelerate development timelines, lower costs, and enhance decision-making across cell therapy programs.

  10. Streamline Your mAb Manufacturing With Strategic Development And CDMO Compatibility 6/4/2025

    Though the journey to mAb development begins at lab scale, for clinical trials and commercial distribution, a production process must be streamlined and scalable to 2,000 L production and above.